ALK inhibitors for ALK-altered paediatric malignancies
Abstract
The phase 1 dose-escalation trial bfy Matthias Fischer and colleagues 1 Fischer M Moreno L Ziegler DS et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021; (published online Nov 12.)https://doi.org/10.1016/S1470-2045(21)00536-2 Summary Full Text Full Text PDF PubMed Scopus (6) Google Scholar published in The...
Paper Details
Title
ALK inhibitors for ALK-altered paediatric malignancies
Published Date
Dec 1, 2021
Journal
Volume
22
Issue
12
Pages
1646 - 1648
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History